Who
James Paul Kastenmayer
General Counsel
Company insider
Files Form 4 as: General Counsel, ArriVent BioPharma; General Counsel, Spyre Therapeutics; General Counsel, Viela Bio.
In numbers
- Trades disclosed
- 7
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 14 Jan 2020
- Last trade
- 2 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 4 Feb 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 3 Feb 2025filed 14 Feb 2025 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —102,000 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 23 Aug 2022filed 25 Aug 2022 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 15 Mar 2021filed 15 Mar 2021 | Viela Biooption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 14 Jan 2020filed 15 Jan 2020 | Viela Biooption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.